Attorney's Docket No. 5405-252

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: David Rizzieri et al.
Serial No.: 10/008,062
Filed: October 19, 2001
For: **ANTI-TENASCIN MONOCLONAL ANTIBODY THERAPY FOR LYMPHOMA**

Date: February 26, 2002

Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
CITATION UNDER 37 C.F.R. § 1.97

Attached is a list of documents on Form PTO-1449 together with a copy of each identified document. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP.

Respectfully submitted,

Kenneth D. Sibley
Registration No. 31,665

Correspondence Address:

20792
PATENT TRADEMARK OFFICE

Tel (919) 854-1400
Fax (919) 854-1401

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on February 26, 2002.

Lucille H. Gillette Date of Signature: February 26, 2002

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 5405-252	Serial No. 10/008,062
	Applicants: David Rizzieri et al.	
	Filing Date October 19, 2001	Group

U. S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	4.474.893	10/02/84	Reading	436	547	
	2.	4,676,980	06/30/87	Segal et al.	424	85	
	3.	4,816,567	03/28/89	Cabilly et al.	530	387	
	4.	5,624,659	04/29/97	Bigner et al.	424	1.49	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes | No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	5.	Aeschlimann et al., *Identification of Gln726 in nidogen as the amine acceptor in transglutarninase-catalyzed cross-linking of laminin-nidogen complexes*, J Biol Chem., 267:11316-21 (1992).
	6.	Akabani et al., *Dosimetry of ^{131}I-Labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors*, J Nucl Med., 40:631-638 (1999).
	7.	Back et al., *Tenascin expression in activated lymphatic cells and gastrointestinal tracts*, Verh Dtsch Ges Pathol (1996) 80:326 (in German) (with English abstract).
	8.	Bell WR, *The fibrinolytic system in neoplasia*, Sem Throm Hemostat., 22:459-478 (1996).
	9.	Bigner et al., *Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial of results*, J Clin Oncol, 16:2202-2212 (1998).
	10.	Birchall et al., *A microcomputer algorithm for solving first-order compartmental involving recycling*, Health Physics, 56:857-868 (1989).
	11.	Bourdon et al., *Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody*, Cancer Res, 43:2796-2805 (1983).

EXAMINER _____ DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 5405-252	Serial No. 10/008,062
	Applicants: David Rizzieri et al.	
	Filing Date October 19, 2001	Group

	12.	Broll et al., *Expression of tenascin in tumors of the esophagus, small intestine and colorectum*, Gen Diag Pathol, 141:111-119 (1995).
	13.	Bullard et al., *In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies*, J Neurosurg 64:257-262 (1986).
	14.	Bullard et al., *Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs)*, Nuklearmedizin-Nuclear Med, 25:210-215 (1986).
	15.	Folkman, J, *Anti-angiogenesis: new concept for therapy of solid tumors*, Ann. Surg., 175:409-416 (1972).
	16.	Forsberg et al., *Skin wounds and severed nerves heal normally in mice lacking tenascin-C*, Proc Natl Acad Sci USA, 93:6594-6599 (1996).
	17.	Harris et al., *A revised European-American classification of lymphoid neoplasms: A proposal form the International Lymphoma Study Group*, Blood:1361-1392 (1994).
	18.	Harris et al., *Growth factors and angiogenesis in breast cancer*, Recent Results in Cancer Research, 127:35-41 (1993).
	19.	He et al., *Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein Tenascin*, J. Neuroimmunol., 52:127-137 (1994).
	20.	Hettasch et al., *Tissue transglutaminase expression in human breast cancer*. Lab. Invest., 75:637-645 (1996).
	21.	Huse, M., *Generationof a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda*, Science, 246:1275-1281 (1989).
	22.	Jahkola et al., *Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis*, Int J Cancer, 69:445-447 (1996).
	23.	Jallo et al., *Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis*, Neurosurgery, 41:1052-1059 (1997).
	24.	Kawakatsu et al., *Human carcinoma cells synthesize and secrete tenascin in vitro*, Jpn J Cancer Res. 83:1073-1080 (1992).
	25.	Kojima et al., *Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells*, J Cell Biol., 121:439-448 (1993).
	26.	Kostianovsky et al., *Tenascin-C expression in ultrastructurally defined angiogenic and vasculogenic lesions*, Ultrastructural Pathol, 21:537-544 (1997).
	27.	Kusagawa et al., *Expression and degradation of tenascin-C in human lung cancers*, British J Cancer, 77:98-102 (1998).
	28.	Mackie EJ, *Molecules in focus: tenascin-C*, Int J Biochem Cell Biol, 29:1133-1137 (1997).
	29.	Mackie et al., *Regulation of tenascin-C expression in Bone Cells by TGF-β*, Bone, 22:301-307 (1998).
	30.	Non-Hodgkin's Lymphoma Pathologic Classification Project, *National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas*, Cancer, 49:2112-2135 (1982).
	31.	Reist et al., *Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent*, Clinical Cancer Research., 4:2495-2502 (1998).
	32.	Ribatti et al., *Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lyumphomas. An immunohistochemical and ultrastructural study*, Eur J. Haematology, 56:45-53 (1996).

EXAMINER _____ DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)			Attorney Docket Number 5405-252	Serial No. 10/008,062
			Applicants: David Rizzieri et al.	
			Filing Date October 19, 2001	Group
	33.	Rizzieri et al., *Markers of angiogenesis, factor VIII and tenascin, correlate with disease activity in patients with non-Hodgkin's lymphoma*, Abstract #4339, Blood 94 (Supp 1): 4339 (1999).		
	34.	Sane et al., *Vitronectin is a substrate for transglutarninases. Biochem Biophys Res Commun.*, 157:115-20 (1988).		
	35.	Schold et al., *Distribution and dosimetry of I-123 labeled monoclonal antibody 81C6 in patients with anaplastic glioma*, Invest Radiol, 28:488-496 (1993).		
	36.	Soini et al., *Tenascin in reactive lymph nodes and in malignant lymphomas*, Pathol Res Pract., 188:1078-1082 (1992).		
	37.	Takvorian et al., *Treatment of relapsed non-Hodgkin's lymphoma utilizing purged autologous bone marrow*, UCLA Symposia on Molecular and cellular Biology, New Series, 27:113-120 (1985).		
	38.	Turner et al., *Complexation of fibronectin with tissue transglutaminase*, Biochemistry, 28: 628-635 (1989).		
	39.	Upchurch et al., *Cellular transglutaminase has affinity for extracellular matrix*, In Vitro Cell Dev Biol., 23:795-800 (1987).		
	40.	Vacca et al., *Expression of tenascin is related to histologic malignancy and angiogenesis in B-cell non-hodgkin's lymphomas*, Leukemia and Lymphoma, 22:473-481 (1996).		
	41.	Walker et al., *Interaction of human IgG chimeric antibodies with the human FcRI and FcRIIi receptors: requirements for antibody-mediated host cell-target cell interaction*, Molec. Immun., 26:403-11 (1989).		
	42.	Zagzag et al., *Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro*, Cancer Research, 56:182-189 (1996).		
	43.	Zalutsky et al., *A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine*, Appl. Radiat. Isot., 38:1051-1055 (1987).		
	44.	Zalutsky et al., *Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent*, Nucl Med Biol, 23:449-458 (1996).		

EXAMINER _____ DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.